

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

LUPIN LTD. and LUPIN PHARMACEUTICALS INC., INNOPHARMA  
LICENSING, INC., INNOPHARMA LICENSING LLC, INNOPHARMA INC.,  
INNOPHARMA LLC, MYLAN PHARMACEUTICALS INC., and MYLAN INC.  
Petitioner

v.

SENJU PHARMACEUTICAL CO., LTD.,  
Patent Owner

---

Case IPR2015-01097 (Patent 8,754,131 B2)<sup>1</sup>  
Case IPR2015-01100 (Patent 8,927,606 B1)<sup>2</sup>  
Case IPR2015-01105 (Patent 8,871,813 B2)<sup>34</sup>

---

**PATENT OWNER'S MOTION TO EXPUNGE  
UNDER 37 C.F.R. § 42.56**

---

<sup>1</sup> Case IPR2016-00089 has been joined with this proceeding.

<sup>2</sup> Case IPR2016-00091 has been joined with this proceeding.

<sup>3</sup> Case IPR2016-00090 has been joined with this proceeding.

<sup>4</sup> A word-for-word identical paper has been filed in each proceeding identified in the heading.

## **I. Statement of Relief Requested**

Pursuant to 37 C.F.R. § 42.56, Patent Owner requests that the Board expunge from the record the confidential versions of Paper Nos. 23 and 24 and Exs. 1099, 1120, 1122, 1123, 1154, 1181, 2082, 2096, 2102, 2103, 2110, 2116, 2126, 2128, 2130, 2251, 2258, 2267-2278, 2291-2293, 2294, and 2323, for the reasons stated herein.

## **II. Background**

On July 29, 2016, Patent Owner filed a Renewed Motion to Seal concerning a number of Patent Owner's exhibits, listed below (*see* Paper No. 68), and on August 1, 2016, Patent Owner filed a Second Renewed Motion to Seal concerning additional exhibits, also listed below, (*see* Paper No. 69). On September 15, 2016, the Board granted Patent Owner's two motions to seal (*see* Paper Nos. 73, 74), sealing all or portions of the following papers and exhibits:

- Patent Owner's Response (citing to confidential exhibits), Paper Nos. 23 and 24 (filed February 25, 2016).
- Excerpts of Patent Owner's New Drug Application: Ex. 2096 (filed July 29, 2016); Ex. 2102 (filed July 29, 2016); Ex. 2103 (filed July 29, 2016);

Ex. 2110 (filed July 29, 2016); Ex. 2251 (filed July 29, 2016); Exs. 2291-2293 (filed July 29, 2016).<sup>5</sup>

- Information related to alleged commercial success of Patent Owner's product from a related district court case: Ex. 2258 (filed February 25, 2016); Ex. 2323 (filed May 5, 2016).
- Materials related to third-party BioScience's testing procedures: Exs. 2267-2278, 2294 (filed February 25, 2016).
- Expert Declarations: Hofmann (Ex. 1122) (filed April 22, 2016); Williams (Ex. 2082) (filed February 25, 2016); Trattler (Ex. 2116) (filed July 29, 2016); Myers (Ex. 2126) (filed July 29, 2016); Paulson (Ex. 2128) (filed February 25, 2016); and Jarosz (Ex. 2130) (filed July 29, 2016).<sup>6</sup>

---

<sup>5</sup> Revised, confidential versions of Exs. 2096, 2102, 2103, 2110, 2251, and 2291-2293 were filed on July 29, 2016 to conform with the marking requirements of the Stipulated Protective Order.

<sup>6</sup> Revised, confidential versions of Exs. 2116, 2126, and 2130 were filed on July 29, 2016 to conform with the marking requirements of the Stipulated Protective Order and to remove redactions to information (specifically expert testimony) which Patent Owner no longer sought to seal.

IPR2015-01097 (Patent 8,754,131 B2)  
IPR2015-01100 (Patent 8,927,606 B1)  
IPR2015-01105 (Patent 8,871,813 B2)

- Transcripts of Expert Cross Examinations: Dr. Paulson (Ex. 1123) (filed April 22, 2016); Dr. Trattler (Ex. 1120) (filed April 22, 2016); Dr. Williams (Ex. 1099) (filed April 22, 2016); and Mr. Hofmann (Ex. 1181) (excerpts from transcript) (filed May 18, 2016).

As outlined in the Joint Stipulation filed herewith, in its Final Written Decision of September 12, 2016, the Board referred to paragraphs containing sealed, confidential information, in the following papers and exhibits:

- Patent Owner's Response (Paper No. 23),
- Hofmann Declaration (Ex. 1122),
- Ex. 1154
- Williams Declaration (Ex. 2082), and
- Jarosz Declaration (Ex. 2130).

As also noted in the Joint Stipulation, the parties will file revised, public versions of Patent Owner's Response and Exs. 1122, 1154, 2082, and 2130, leaving unredacted the portions of those papers and exhibits cited by the Board in the Final Written Decision.

### **III. Reasons for the Relief Requested**

In the Board's Order of September 15, 2016, the Board noted that, with respect to confidential information not cited in the Final Written Decision, a party

seeking to maintain the confidentiality of such information may file a motion to expunge the information from the record prior to it becoming public. (*See* Paper No. 73 at 6.) Accordingly, Patent Owner requests the following papers and exhibits containing confidential information sealed by the Board, but not referred to in the Board's Final Written Decision, be expunged from the record:

- Patent Owner's Response (citing to confidential exhibits), Paper Nos. 23 and 24 (filed February 25, 2016).
- Excerpts of Patent Owner's New Drug Application: Ex. 2096 (filed July 29, 2016); Ex. 2102 (filed July 29, 2016); Ex. 2103 (filed July 29, 2016); Ex. 2110 (filed July 29, 2016); Ex. 2251 (filed July 29, 2016); Exs. 2291-2293 (filed July 29, 2016).
- Information related to alleged commercial success of Patent Owner's product from a related district court case: Ex. 2258 (filed February 25, 2016)<sup>7</sup>; Ex. 2323 (filed May 5, 2016).
- Materials related to third-party BioScience's testing procedures: Exs. 2267<sup>8</sup>-78, 2294 (filed February 25, 2016).<sup>9</sup>

---

<sup>7</sup> Only the confidential version of Ex. 2258 should be expunged.

<sup>8</sup> Only the confidential version of Ex. 2267 should be expunged.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.